Recursion Pharmaceuticals Lays Off 20% of Staff Amid Pipeline Cutbacks
Recursion Pharmaceuticals announced a 20% reduction in workforce as part of a restructuring plan.
The layoffs are connected to the narrowing of the company’s pipeline, focusing on oncology and rare diseases.
Recursion expects to incur nearly $11 million in related expenses, including severance and employee benefits.
The company aims to reduce cash burn, keeping 2025 burn below $450 million and 2026 burn under $390 million.
The restructuring extends Recursion’s cash runway into the fourth quarter of 2027.
The layoffs are a response to ongoing biotech industry challenges and reduced investor funding.
Recursion’s shares have fallen 21% year-to-date.